Annexon Reports Q4 2025 Financials, Exceeds EPS Estimates, and Details Key Clinical Milestones

summarizeSummary

Annexon reported better-than-expected Q4 2025 financial results, a strong cash position extending its runway into H2 2027, and outlined multiple significant clinical milestones for its late-stage pipeline in 2026.

check_boxKey Events

• Q4 2025 Financial Results Exceed Expectations

  Annexon reported a net loss of $0.28 per share for the fourth quarter of 2025, outperforming analyst estimates.

• Strong Cash Position and Extended Runway

  The company ended 2025 with approximately $238.3 million in cash, cash equivalents, and short-term investments, providing an anticipated operational runway into the second half of 2027.

• Pivotal Phase 3 Data for GA Expected in Q4 2026

  Topline pivotal Phase 3 ARCHER II trial data for vonaprument in Geographic Atrophy (GA) is anticipated in the fourth quarter of 2026, with potential to be the first vision-preserving therapy for GA.

• European MAA Filed for GBS Therapy

  A Marketing Authorization Application (MAA) for tanruprubart in Guillain-Barré Syndrome (GBS) has been filed in Europe, with U.S./European FORWARD study data expected to support a planned BLA submission in 2026.

auto_awesomeAnalysis

Annexon's latest 8-K filing provides a comprehensive update on its financial performance and critical pipeline advancements. The company reported a fourth-quarter net loss per share of $0.28, which was better than analyst expectations, indicating improved financial management or revenue performance. Crucially for a biotech, Annexon maintains a strong balance sheet with $238.3 million in cash, cash equivalents, and short-term investments, providing an anticipated operational runway into the second half of 2027. This financial stability supports the continued progression of its late-stage clinical programs. The filing highlights significant upcoming milestones, including pivotal Phase 3 data for vonaprument in Geographic Atrophy expected in Q4 2026, the European MAA filing for tanruprubart in Guillain-Barré Syndrome, and anticipated BLA submission in 2026. Additionally, Proof-of-Concept data for the oral C1 inhibitor ANX1502 is expected in 2026. These clinical updates are vital for the company's long-term value creation and represent key catalysts for investors.